NASDAQ:AKTX Akari Therapeutics (AKTX) Stock Price, News & Analysis $9.76 -0.30 (-2.98%) Closing price 09/25/2026 03:59 PM EasternExtended Trading$10.10 +0.35 (+3.53%) As of 09/25/2026 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Akari Therapeutics Stock (NASDAQ:AKTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Akari Therapeutics alerts:Sign Up Key Stats Today's Range$9.30▼$10.2550-Day Range$7.00▼$11.4752-Week Range$3.02▼$46.00Volume71,534 shsAverage Volume85,418 shsMarket Capitalization$19.03 millionP/E RatioN/ADividend YieldN/APrice Target$32.33Consensus RatingModerate Buy Company Overview Akari Therapeutics plc is a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases. The company’s research is focused on modulating the complement system and inflammatory pathways that contribute to tissue damage and disease progression. Akari’s lead investigational product is nomacopan, a recombinant small protein originally derived from tick saliva. Nomacopan is designed to inhibit complement component C5 and leukotriene B4, two pathways involved in inflammation. The company is also developing PAS-nomacopan, a longer-acting formulation intended to extend treatment duration. The company has investigated its therapies in conditions including pediatric hematopoietic stem-cell-transplant-associated thrombotic microangiopathy and bullous pemphigoid. Akari’s programs remain in clinical development, and its therapies have not been established as approved treatments for these indications. Akari Therapeutics is headquartered in the United Kingdom and conducts its development activities through international clinical and research programs. The company is led by Chief Executive Officer Clive Richardson and is listed on the Nasdaq Capital Market under the symbol AKTX.AI Generated. May Contain Errors. Read More Akari Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreAKTX MarketRank™: Akari Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 195th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingAkari Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAkari Therapeutics has a consensus price target of $32.33, representing about 231.3% upside from its current price of $9.76.Amount of Analyst CoverageAkari Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Akari Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioAkari Therapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Akari Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.82% of the float of Akari Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkari Therapeutics has a short interest ratio ("days to cover") of 0.11, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akari Therapeutics has recently decreased by 64.26%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkari Therapeutics does not currently pay a dividend.Dividend GrowthAkari Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.94 News SentimentAkari Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Akari Therapeutics this week, compared to 3 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Akari Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders32.20% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions5.06% of the stock of Akari Therapeutics is held by institutions.Read more about Akari Therapeutics' insider trading history. Receive AKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKTX Stock News HeadlinesAkari Therapeutics PLC (NASDAQ:AKTX) Stock Has Consensus Price Target of $32.33September 27 at 1:14 AM | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Stock Passes Above 50 Day Moving Average - What's Next?September 17, 2026 | americanbankingnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 27 at 1:00 AM | The Oxford Club (Ad)Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare ForumsSeptember 8, 2026 | globenewswire.comAkari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand ConferenceAugust 27, 2026 | globenewswire.comAkari targets mid-2027 for human trial of differentiated cancer therapyAugust 18, 2026 | msn.comAkari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC StrategyAugust 18, 2026 | globenewswire.comAkari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload PlatformAugust 13, 2026 | globenewswire.comSee More Headlines AKTX Stock Analysis - Frequently Asked Questions How have AKTX shares performed this year? Akari Therapeutics' stock was trading at $11.56 at the beginning of 2026. Since then, AKTX shares have decreased by 15.6% and is now trading at $9.76. How were Akari Therapeutics' earnings last quarter? Akari Therapeutics PLC (NASDAQ:AKTX) issued its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($312.00) EPS for the quarter, missing analysts' consensus estimates of ($112.00) by $200.00. When did Akari Therapeutics' stock split? Akari Therapeutics's stock reverse split on the morning of Thursday, August 17th 2023.The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Akari Therapeutics? Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Akari Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akari Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), Meta Platforms (META) and GE Aerospace (GE). Company Calendar Last Earnings3/31/2020Today9/27/2026Next Earnings (Estimated)12/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 As of 2 days ago, AKTX's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AKTX CIK1541157 Webwww.akaritx.com Phone(929) 274-7510Fax646-843-9352Employees5Year Founded2014Price Target and Rating Average Price Target for Akari Therapeutics$32.33 High Price Target$40.00 Low Price Target$27.00 Potential Upside/Downside+231.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.30 million Net MarginsN/A Pretax MarginN/A Return on Equity-147.45% Return on Assets-74.70% Debt Debt-to-Equity RatioN/A Current Ratio0.60 Quick Ratio0.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$24.75 per share Price / Book0.39Miscellaneous Outstanding Shares1,950,000Free Float1,320,000Market Cap$19.03 million OptionableNot Optionable Beta1.43 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:AKTX) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
